Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
12.10.2015
River Vision Announces Completion of Enrollment in Graves' Orbitopathy Study
NEW YORK, Oct. 9, 2015 /PRNewswire-iReach/ -- River Vision Development Corp. (RVDC) today announced the completion of enrollment of a Phase 2 clinical study of RV001 (teprotumumab) for the treatment of Graves' Orbitopathy (GO). RV001 is a fully human IGF-1 receptor antagonist antibody with a safety database comprised of more than 700 cancer patients. The study is being conducted at 15 sites in the US and Europe and has enrolled 88 patients with moderate to severe disease.
Dato
07.10.2015
NEW DATA FROM OXFORD UNIVERSITY HOSPITALS DEMONSTRATE SUPERIOR OUTCOME WITH CERAMENT™ ANTIBIOTIC ELUTING BONE SUBSTITUTE COMPARED TO COLLAGEN AND CALCIUM SULFATE IN THE MANAGEMENT OF CHRONIC OSTEOMYELITIS

·         50% Less Fracture Rates with CERAMENT™ with Gentamicin

·         50% Less Infection Recurrence with CERAMENT™ with Gentamicin

·         313 Patients Total in All Groups with a Minimum of 1 Year Follow-Up

Lund, Sweden, (PRNEWSWIRE) October 6, 2015 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced new data from the Bone Infection Unit at the Nuffield Orthopaedic Centre (part of Oxford University Hospitals) as presented at the recent European Bone & Joint Infection Society (EBJIS) meeting.  The study, a comparative evaluation of three local antibiotic delivery materials used as bone defect fillers after excision of chronic osteomyelitis, found CERAMENT™ with Gentamicin performed better in all primary outcomes; recurrence rate, fracture rate and wound leakage rate, despite a higher percentage of compromised Class B hosts.  The three study groups encompassed a total of 313 patients each with a minimum 1- year follow-up.  The group including CERAMENT™ with Gentamicin resulted in fifty percent less fractures, fifty percent less infection recurrences and fewer prolonged wound leaks as compared with the collagen or calcium sulfate products.  

Dato
29.09.2015
Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial of VTS-270 for Treatment of Niemann-Pick Type C1 (NPC) Disease

During its first year of operations, Vtesse advances lead program into late-stage, pivotal trial and launches www.theNPCstudy.com

- Goal is to establish a clear foundational data set on the safety and efficacy of VTS-270 for treatment of NPC

GAITHERSBURG, Md., Sept. 28, 2015 /PRNewswire/ -- Vtesse, Inc. today announced that the first three patients have been screened for inclusion in its pivotal Phase 2b/3 clinical trial with VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC). This clinical trial follows a Phase 1 study conducted by researchers at the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). 

Dato
29.09.2015
CERAMENT™ ANTIBIOTIC ELUTING BONE SUBSTITUTES FOR THE MANAGEMENT OF OSTEOMYELITIS PROMINENT AT THE 34TH ANNUAL MEETING OF THE EUROPEAN BONE & JOINT INFECTION SOCIETY (EBJIS)

CERAMENT™ with Gentamicin Shown to Decrease Recurrence of Infection and Increase Bone Formation

Lund, Sweden, (PRNEWSWIRE) September 24, 2015 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the presentation of new clinical data with the Company’s platform bone void filler, CERAMENT™ with antibiotics which was presented at the 34th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) on September 10-12 in Lisboa, Portugal.  CERAMENT™|G is the first CE-marked antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis and was prominently featured at EBJIS, a European association of orthopedic surgeons, trauma surgeons, infection specialists and microbiologists.  

Dato
09.09.2015
Biom’Up secures EUR 31,3 million in Series C financing from Bpifrance Large Venture, Gimv and Lundbeckfond Ventures
St-Priest, 9 September 2015, 7:30 AM CET – Biom’Up today announced that the company has secured EUR 31,3 million in a Series C financing round from an investment syndicate consisting of Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, alongside its existing shareholders (InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l’Améliane) and the company’s management team. This third institutional financing round represents a milestone for the international growth and scaling of the business. 
Dato
08.09.2015
Sanifit raises €36.6M ($41.3M) in Series C financing round
Financing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through
phase II/III for calciphylaxis.


Palma de Mallorca, Spain, September 8, 2015 - Laboratoris Sanifit S.L., a clinical-stage
biopharmaceutical company, today announces that it has raised €36.6M ($41.3M) in a Series
C financing round. The company is focused on the development of SNF472, an experimental
drug for the treatment of cardiovascular diseases linked to calcification in patients with End
Stage Renal Disease (ESRD) undergoing haemodialysis.
Dato
25.08.2015
CERAMENT™ WITH ANTIBIOTICS TO BE FEATURED EXTENSIVELY AT THE 34TH ANNUAL MEETING OF THE EUROPEAN BONE & JOINT INFECTION SOCIETY (EBJIS)
Lund, Sweden, (PRNEWSWIRE) August 25, 2015 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that its platform bone void filler, CERAMENT™ with antibiotics, will have a significant presence at the upcoming 34th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) taking place September 10-12 in Lisboa, Portugal. The annual meeting will feature twelve presentations and posters highlighting the outstanding long-term clinical benefits of CERAMENT™|G, the first antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.
Dato
17.08.2015
Veloxis Pharmaceuticals Envarsus® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015.
Dato
10.08.2015
Vtesse, Inc. Announces Preliminary Data from Ongoing Phase 1 Study of VTS-270 for Treatment of Niemann-Pick Disease Type C
Post-Hoc Analyses of Data Show Preliminary Evidence of Overall Disease Stabilization with Improvement in Several Disease Domains
Dato
03.08.2015
Ziarco Appoints Mike Grey as Executive Chairman of Board of Directors
CANTERBURY, UK, 20 JULY, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Mike Grey as Executive Chairman of its Board of Directors, effective immediately. Mr. Grey first joined the Company’s board as an independent director in December 2014. 
Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste